LL-37 in Canada: A Research Guide to the Antimicrobial Peptide and Skin Barrier

Why LL-37 belongs in the skin archive#

LL-37 Canada searches usually come from researchers who have encountered the peptide in immunology, microbiology, dermatology, or wound-healing literature and want to know whether it can be sourced responsibly for laboratory work. The molecule is not a growth-hormone secretagogue, a GLP-1 analogue, or a melanocortin agonist. It is an antimicrobial peptide with broad immunomodulatory activity, and its most interesting research questions sit at the boundary between infection biology, cutaneous innate immunity, and inflammatory skin disease.

That makes LL-37 a natural addition to Northern Compound's skin category, even though its commercial home is often grouped with recovery-repair peptides. The reason is simple: skin is where much of the best-characterised LL-37 biology happens. Keratinocytes produce it. It is processed by kallikreins in the epidermis. It is deficient in atopic dermatitis, overexpressed in psoriasis, and abnormally cleaved in rosacea. It kills bacteria, modulates neutrophil and macrophage recruitment, influences cytokine networks, and participates in wound repair. Those are not recovery-only questions; they are skin-barrier and cutaneous-immunology questions.

This guide treats LL-37 as research-use-only material. It does not provide dosing instructions, does not recommend self-experimentation, and does not present research peptides as substitutes for Health Canada-authorised dermatological care, antimicrobial therapy, or specialist evaluation. The goal is narrower: define the molecule, map the skin-relevant evidence, distinguish its roles in different dermatological contexts, and explain what a Canadian lab should demand before sourcing LL-37 for a documented study.

What LL-37 is at the molecular level#

LL-37 is the active C-terminal peptide released from human cationic antimicrobial protein 18 (hCAP-18), the only known human cathelicidin. The precursor is an 18 kDa protein stored in neutrophil granules and expressed in epithelial cells, including keratinocytes, as well as in macrophages, mast cells, and certain lymphocytes. Proteolytic cleavage releases the 37-amino-acid peptide, which assumes an amphipathic alpha-helical structure in membrane-like environments.

The sequence is LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES. At physiological pH the peptide carries a net positive charge of approximately +6, which contributes to its affinity for negatively charged microbial membranes and its ability to disrupt bacterial cell walls. In aqueous solution it is largely disordered; in lipophilic environments it folds into a helix spanning roughly residues 2 through 31, hinged around lysine-12. That conformational flexibility matters for mechanism because it allows the peptide to interact with membranes, lipoproteins, nucleic acids, and host-cell receptors under different conditions.

The skin context begins with expression. Keratinocytes constitutively produce hCAP-18 and can upregulate it in response to injury, infection, vitamin D signalling, and inflammatory cytokines. In neutrophils the concentration is high—estimated around 40 μM or 630 μg per 10⁹ cells—making LL-37 one of the most abundant peptides released during neutrophil degranulation. When a wound breaches the epidermis, both resident keratinocytes and infiltrating neutrophils contribute LL-37 to the local microenvironment.

For research procurement, the first quality-control implication is identity. A supplier offering "LL-37" should specify whether the material is the full 37-residue human cathelicidin peptide, a truncated analogue, a D-amino-acid variant, or a different sequence altogether. The research literature on hCAP-18-derived LL-37 assumes the natural L-form sequence unless stated otherwise. If a vial contains a modified analogue, the mechanistic references may not apply.

The skin barrier context: antimicrobial and immunomodulatory roles#

The skin barrier is not simply a physical wall. It is an active immune interface. Keratinocytes express pattern-recognition receptors, produce cytokines, and release antimicrobial peptides that shape the cutaneous microbiome and respond to pathogens. LL-37 is one of the most important of those peptides, alongside beta-defensins, psoriasin, and dermcidin.

In healthy skin, LL-37 contributes to antimicrobial defence against bacteria, fungi, and viruses. Its membrane-disruptive activity is well documented against Gram-positive organisms including Staphylococcus aureus and Gram-negative organisms including Pseudomonas aeruginosa. At sub-lethal concentrations it can also inhibit biofilm formation, which is relevant to chronic wound and skin-infection models. A review in Frontiers in Immunology summarises LL-37's broad-spectrum activity, anti-biofilm effects, and direct wound-healing properties in polymicrobial infection models (Duplantier and van Hoek, 2013).

Beyond direct microbial killing, LL-37 acts as a chemoattractant and signalling molecule. It can recruit neutrophils, monocytes, and T cells through formyl-peptide receptor-like 1 and other receptors. It modulates cytokine production, influences dendritic-cell maturation, and has been reported to promote angiogenesis and re-epithelialisation in wound models. Those host-directed effects are why LL-37 cannot be reduced to a simple antibiotic surrogate. In research design, the peptide is better understood as a multifunctional innate-immunity probe that affects both microbes and host cells.

The concentration dependence of those effects is critical. At low concentrations LL-37 may promote cell migration and tissue repair. At high concentrations it can be cytotoxic to mammalian cells, including keratinocytes and endothelial cells, through membrane disruption and other mechanisms. That biphasic behaviour means research protocols must define concentration ranges carefully and include viability controls. A study that reports only one concentration may miss the full biological picture.

LL-37 in atopic dermatitis: deficiency and consequences#

Atopic dermatitis (AD) is one of the clearest disease contexts for LL-37 skin research. In AD, lesional and often non-lesional skin shows reduced expression of LL-37 compared to healthy skin. That deficiency is not merely a biomarker; it is mechanistically linked to increased susceptibility to bacterial colonisation, particularly Staphylococcus aureus.

A PubMed-indexed review in Annals of Dermatology outlines the role of cathelicidin LL-37 in inflammatory skin disease, noting that AD is characterised by disturbed induction of the peptide, resulting in defective antimicrobial barrier function (PMID 22577261). More recent work has confirmed that LL-37 is the only antimicrobial peptide consistently impaired in both non-lesional and lesional AD skin, distinguishing it from beta-defensins and other peptides that may be preserved. That specific deficit makes LL-37 a compelling target for mechanistic studies of barrier dysfunction.

The research implication is that AD models can use LL-37 deficiency as a variable. A researcher might ask whether exogenous LL-37 restores antimicrobial activity in AD-mimetic keratinocyte cultures, whether it alters S. aureus colonisation dynamics in tissue models, or whether it modulates the T-helper-2-skewed cytokine environment associated with AD. Those are legitimate mechanistic questions. They should not be confused with therapeutic claims. Adding LL-37 to a cell-culture model is not the same as treating atopic dermatitis in a person, and Northern Compound does not frame research peptides as treatments.

Vitamin D signalling is another relevant axis. 1,25-dihydroxyvitamin D3 can upregulate LL-37 expression via the vitamin D receptor and coactivator pathways. That interaction has been proposed as part of the mechanistic link between vitamin D status and skin immunity. For research design, it means that vitamin D supplementation or VDR modulation in cell or tissue models may confound LL-37-dependent endpoints unless controlled.

LL-37 in psoriasis: the overexpression paradox#

Psoriasis presents the opposite pattern: lesional skin shows elevated LL-37 expression compared to healthy skin. That overexpression creates a mechanistic puzzle. If LL-37 is antimicrobial and reparative, why would more of it be present in a disease characterised by inflammation, hyperproliferation, and plaque formation?

Part of the answer lies in the peptide's immunomodulatory complexity. In psoriasis, LL-37 can form complexes with self-DNA released from damaged cells. Those complexes are recognised by Toll-like receptor 9 on plasmacytoid dendritic cells, triggering type I interferon production and amplifying autoimmune inflammation. In this context, LL-37 is not merely a defender; it is a participant in an aberrant innate-immune loop that drives disease pathology.

The same Annals of Dermatology review notes that psoriasis is characterised by cathelicidin overexpression, but whether pro- or anti-inflammatory functions predominate in lesional skin remains unclear (PMID 22577261). That uncertainty is scientifically productive because it generates testable hypotheses. A researcher might ask whether LL-37-DNA complex formation depends on peptide concentration, DNA length, or the presence of other inflammatory mediators. They might ask whether blocking complex formation reduces interferon response in psoriasis-relevant models. They might compare LL-37 from different sources—endogenous keratinocyte production versus exogenous addition—to see whether source and concentration alter functional outcome.

For Canadian sourcing, those research questions place additional demands on material characterisation. If a study is examining LL-37-DNA interactions, the peptide must be highly purified because contaminants such as endotoxin, residual synthesis reagents, or truncated sequences could themselves nucleate immune complexes or alter TLR signalling. A generic purity claim is insufficient when the mechanism depends on precise molecular behaviour.

LL-37 in rosacea: processing gone wrong#

Rosacea adds a third dermatological angle: aberrant proteolytic processing. In rosacea skin, cathelicidin expression is not necessarily low, but the protease environment is altered, leading to abnormal cleavage of LL-37 into pro-inflammatory fragments. Those fragments appear to trigger inflammation, erythema, and telangiectasia rather than orderly antimicrobial defence.

The proposed mechanism involves several steps. Environmental triggers such as ultraviolet light increase vitamin D synthesis, which induces cathelicidin expression in keratinocytes. At the same time, protease activity is enhanced, possibly related to Demodex mite colonisation and chitin-mediated Toll-like receptor 2 activation. The resulting proteolytic milieu cleaves LL-37 into fragments that retain immunostimulatory activity but lack the orderly spatial and temporal control seen in healthy skin.

This processing story is important for research because it shifts attention from peptide quantity to peptide quality. A study that measures only total LL-37 concentration may miss the critical variable of fragment profile. Analytical methods such as mass spectrometry, chromatography, or specific antibody detection may be needed to distinguish full-length LL-37 from truncated or modified forms. For researchers sourcing exogenous peptide, the implication is that the material should be verified as intact, full-length LL-37 unless the study explicitly intends to examine fragments or analogues.

Therapeutic agents used in rosacea—including doxycycline, azelaic acid, and retinoids—may exert benefit partly by interfering with this pro-inflammatory processing system. That observation creates opportunities for mechanistic research but should not be read as evidence that exogenous LL-37 is a rosacea treatment. The disease involves dysregulated endogenous processing, not simply peptide deficiency.

Wound healing and tissue repair#

Outside of specific dermatoses, LL-37 is extensively studied in wound-healing models. The peptide promotes re-epithelialisation by stimulating keratinocyte migration and proliferation. It supports angiogenesis through effects on endothelial cells. It modulates the inflammatory phase of repair, potentially accelerating transition to proliferation and remodelling. And it maintains antimicrobial surveillance in the wound bed, reducing bioburden that might otherwise stall healing.

The Frontiers in Immunology review by Duplantier and van Hoek highlights LL-37's potential for polymicrobial infected wounds, particularly chronic diabetic foot ulcers and combat wounds where biofilm-forming P. aeruginosa and S. aureus often persist (PMC3699762). In chronic wounds, endogenous LL-37 expression is frequently reduced compared to acute wounds or healthy skin. That deficiency has been proposed as a contributing factor to chronic infection susceptibility and delayed closure.

Research design in this area must attend to formulation and delivery. LL-37 is susceptible to proteolytic degradation in wound fluid and plasma. Glycosaminoglycans such as dermatan sulfate can attenuate its activity. P. aeruginosa elastase can cleave it. These environmental vulnerabilities mean that exogenous LL-37 added to a wound model may behave differently depending on pH, protease content, microbial load, and the presence of matrix materials. A study that adds peptide to sterile cell culture may observe different kinetics than a study using ex vivo wound tissue or a polymicrobial biofilm model.

D-amino-acid analogues such as D-LL-37 have been developed to resist protease degradation. In infection models, D-LL-37 can show superior persistence and efficacy compared to the native L-form. Researchers interested in stability questions should verify whether their sourced material is the L-form, a D-form, or another analogue, because the literature reference depends on that distinction.

Research design considerations for skin models#

LL-37 research is model-sensitive. The peptide behaves differently in purified microbial suspensions, keratinocyte monocultures, reconstructed human epidermis, ex vivo skin, animal wounds, and human chronic wounds. Each model answers a different question, and none of them automatically validates therapeutic use.

Microbial assays are useful for determining minimum inhibitory concentrations, bactericidal kinetics, and biofilm inhibition. They should include appropriate controls: a reference antibiotic, a peptide-free vehicle, and a viability stain to confirm that observed killing is not an artefact of pH or solvent. Because LL-37 is cationic, buffer composition and ionic strength can alter activity significantly.

Keratinocyte cultures allow study of cell migration, proliferation, cytokine release, and receptor signalling. They should include viability assays because LL-37 cytotoxicity can confound apparent stimulatory effects. A culture that loses viability may release inflammatory mediators that are misread as active peptide responses.

Reconstructed epidermis and ex vivo skin add tissue architecture, barrier properties, and stratified cell types. They are more expensive and variable but also more translationally relevant for questions about penetration, distribution, and local tissue response. If the research question involves topical application, these models are closer to the intended context than submerged cell culture.

Animal wound models allow study of whole-organism repair kinetics, angiogenesis, immune infiltration, and infection control. They introduce species differences in cathelicidin biology—mice express CRAMP, not LL-37—which limits direct extrapolation to human skin. Humanised or knockout models may be needed for mechanism-specific claims.

A disciplined Canadian researcher should define the model's limitations in the study record and avoid claiming therapeutic efficacy from preclinical data alone.

Comparing LL-37 with adjacent skin and recovery peptides#

The skin and recovery categories overlap because wound healing and barrier repair are continuous biological processes. LL-37 sits in the immunology-antimicrobial space, while adjacent peptides ask different questions.

GHK-Cu is primarily a copper-signalling and extracellular-matrix peptide. Its research frame is fibroblast behaviour, collagen and elastin turnover, and tissue remodelling. It does not have significant antimicrobial activity against the pathogens typically studied with LL-37, and its mechanism does not involve cathelicidin receptors or TLR9 complex formation. A study comparing GHK-Cu and LL-37 in the same wound model could be informative, but the two peptides are not mechanistic substitutes.

BPC-157 is a body-protection compound studied around angiogenesis, tendon and ligament repair, and gastrointestinal healing. Its mechanism is distinct from LL-37, involving growth-factor pathways, nitric oxide signalling, and cytoskeletal organisation. In wound-healing models, BPC-157 and LL-37 might produce similar endpoint improvements through different intermediate steps. A combination study could examine whether their mechanisms converge or complement, but that requires careful endpoint selection.

TB-500 is a thymosin beta-4 fragment associated with cell migration, actin regulation, and anti-inflammatory modulation. Like BPC-157, it is more closely tied to structural repair and cell-motility pathways than to antimicrobial defence. In a skin-wound programme, TB-500 might be selected for re-epithelialisation kinetics, while LL-37 might be selected for infection control and innate-immune modulation.

|| Compound | Main research lane | Key caution | || --- | --- | --- | || LL-37 | Antimicrobial defence, innate immunity, skin barrier, inflammatory dermatoses | Concentration-dependent cytotoxicity; protease sensitivity; fragment biology in disease models | || GHK-Cu | Extracellular matrix, fibroblast signalling, copper-peptide remodelling | Not antimicrobial; mechanism is not cathelicidin signalling | || BPC-157 | Angiogenesis, tissue repair, growth-factor modulation | Mechanism is distinct from innate-immunity peptides; not a microbial defence agent | || TB-500 | Cell migration, actin regulation, anti-inflammatory repair | Different primary mechanism; not a direct antimicrobial |

A well-designed skin research programme would select the peptide that matches the mechanistic question. If the hypothesis concerns antimicrobial barrier dysfunction and S. aureus colonisation, LL-37 is more relevant than GHK-Cu. If the hypothesis concerns collagen organisation in scar remodelling, GHK-Cu or BPC-157 may be more appropriate. If the hypothesis is about immune-mediated inflammation in psoriasis, LL-37's complex biology may be directly relevant in ways that tissue-repair peptides are not.

Canadian sourcing: what a credible LL-37 COA should show#

A short peptide is not automatically trustworthy because it is short. LL-37 is chemically tractable, which means documentation should be easier, not optional. A Canadian lab evaluating LL-37 should ask for batch-specific paperwork before placing the compound into a notebook.

At minimum, the certificate of analysis should identify the exact peptide and sequence, state the lot number, report HPLC purity with a chromatogram or method summary, and confirm identity by mass spectrometry. The supplier should state the salt form, net peptide content or fill target, appearance, recommended storage conditions, and expiry or retest date. For models sensitive to innate immune activation, endotoxin and microbial expectations should be addressed. Residual solvent and water-content data are useful when available.

Storage matters. Lyophilised peptides are generally more stable when kept sealed, dry, protected from light, and cold. Reconstituted material is usually less stable and more vulnerable to contamination, adsorption, oxidation, and repeated freeze-thaw damage. For LL-37 specifically, protease contamination during reconstitution or handling can degrade the peptide before it reaches the assay. Sterile technique, filtered solvents, and aliquot planning are therefore especially important.

The supplier standard should also include operational clarity. Domestic shipping, lot traceability, responsive support, and accessible COAs reduce ambiguity. Northern Compound's Canadian buyer guide explains the broader sourcing framework: verify the product, verify the lot, verify the testing lab where possible, and do not confuse marketing language with analytical evidence.

Safety and compliance cautions#

LL-37 deserves stricter language than many catalogue pages use. It is an innate-immunity effector with concentration-dependent cytotoxicity, and its role in inflammatory disease is complex. In psoriasis it may promote inflammation through DNA complex formation. In rosacea it may generate pro-inflammatory fragments. At high concentrations it can damage host cells. Those properties make it scientifically interesting but also potentially hazardous in uncontrolled contexts.

This article is not a risk-management plan for personal use because Northern Compound does not recommend personal use. The compliance point is simpler: research material is not medicine, and a peptide with antimicrobial literature adjacent to it is not automatically authorised for any individual. Canadian researchers should separate laboratory-grade LL-37 from regulated therapeutic products. They should also avoid language that implies treatment of eczema, psoriasis, rosacea, chronic wounds, or infections for readers.

For studies involving human tissue or subjects, ethics and regulatory oversight apply. In vitro and ex vivo work can answer many mechanistic questions without human exposure. Any clinical research belongs under institutional review, medical oversight, and lawful product sourcing. The fact that LL-37 is an endogenous human peptide does not lower the scientific or ethical threshold for human use.

Analytical pitfalls: when the label is more confident than the vial#

LL-37 is an ideal case study in why peptide sourcing cannot rely on label confidence. The molecule is small enough to synthesise and verify with standard analytical tools, but the commercial peptide market includes truncated sequences, D-amino-acid analogues, and mislabelled materials. A product may be described as LL-37, cathelicidin, antimicrobial peptide, or a fragment, and those descriptions do not all carry the same evidentiary meaning.

For research procurement, the first question is identity. A mass spectrum should be consistent with the declared 37-residue sequence and salt form. HPLC purity should be reported for the same lot, not borrowed from a representative production run. A chromatogram should make it possible to see whether major impurities are present and whether the integration method is plausible. None of this proves biological activity by itself, but it prevents the most basic failure: studying an unknown or mislabelled material while believing it is defined human cathelicidin.

The second question is degradation. LL-37 can be cleaved by proteases, oxidised, adsorbed to surfaces, or lose integrity after poor storage. It does not have the lipidated complexity of semaglutide, but it is still a peptide that requires dry, protected, cold storage before reconstitution and sensible handling after reconstitution. A supplier that ships without temperature consideration, provides no retest date, or treats all peptides as if they share the same stability profile is signalling weak quality control.

The third question is biological contamination. Skin and immune models can be sensitive to endotoxin and microbial material. A keratinocyte assay intended to measure LL-37-mediated migration can be confounded by inflammatory contaminants. If a study measures cytokines, oxidative stress, or viability, contaminant controls become especially important. That is why Northern Compound repeatedly returns to batch documentation: without it, researchers may mistake a supply-chain artefact for a biological finding.

Where LL-37 fits in a Canadian skin research programme#

A well-designed skin research programme would treat LL-37 as one probe among several, not as a generic skin-improvement compound. It can help interrogate antimicrobial barrier function, innate-immune signalling, inflammatory dermatosis mechanisms, and wound-microenvironment biology. It is less useful for extracellular matrix remodelling, collagen-expression questions, or growth-factor signalling unless the hypothesis explicitly links those endpoints to immune-mediated repair.

For example, a programme comparing barrier dysfunction interventions might include LL-37 for antimicrobial and innate-immunity restoration, GHK-Cu for matrix remodelling, and a non-peptide antimicrobial control to separate direct microbial killing from host-directed effects. A programme focused on psoriasis might examine LL-37-DNA complex formation, interferon response, and the effects of exogenous versus endogenous peptide sources. A programme focused on chronic wound infection might study LL-37 in biofilm models, compare L-form and D-form stability, and examine synergy or antagonism with conventional antibiotics.

This is also where internal linking matters for readers. A lab new to peptide sourcing should start with the Canadian buyer guide before comparing vendors. A lab preparing lyophilised material should use the reconstitution guide for handling principles. A reader comparing adjacent mechanism categories can contrast LL-37 with tissue-repair peptides like BPC-157 or TB-500, or with copper-peptide research materials like GHK-Cu, not because they are substitutes, but because the contrast makes mechanism-specific sourcing clearer.

Practical checklist for Canadian LL-37 research sourcing#

Before purchasing LL-37 for a documented research project, a Canadian lab should be able to answer the following questions:

1. Is the product explicitly identified as full-length human LL-37 (L-form) rather than a vague antimicrobial peptide blend, fragment, or D-amino-acid analogue?
2. Does the COA show lot-matched HPLC purity and mass spectrometry identity confirmation?
3. Are sequence, salt form, fill amount, storage conditions, and retest date clearly stated?
4. Does the model require endotoxin or microbial limits, and has the supplier addressed them?
5. Are the internal endpoints mechanistic rather than consumer-facing wellness or treatment claims?
6. Does the protocol include viability controls given the peptide's concentration-dependent cytotoxicity?
7. Does the study avoid human-use, dosing, or therapeutic claims unless it is an authorised clinical protocol?

If any of those answers are missing, the gap should be resolved before the compound enters the study record.

Bottom line#

LL-37 is scientifically interesting because it connects a defined peptide sequence to one of the most active frontiers in skin biology: cutaneous innate immunity. Its roles in atopic dermatitis deficiency, psoriasis overexpression, rosacea processing, and wound-healing modulation show that the same molecule can produce very different biological outcomes depending on concentration, context, and protease environment. Those complexities make it a strong research probe but also a compound that demands careful experimental design.

For Canadian researchers, the disciplined path is to treat LL-37 as research-use-only material, build studies around mechanistic endpoints, insist on batch-level analytical documentation, and keep compliance language clear. A vial is not a protocol. An antimicrobial peptide is not an antibiotic substitute. And a supplier claim is only useful when it can be traced to a molecule, a lot, a method, and a defensible research question.